| 6、问：请问粉针类产品与竞争对手相比优势体现在哪 | | --- | | 里？ | | 答：您好，公司有专业的销售团队；有较强的营销 | | 能力；有稳定的产品质量保证。感谢您的关注。 | | 7、问：化学制药中公司的毛利率偏低，请问为什么？ | | 答：您好，公司药品制造成本的上升，同时药品售 | | 价受到国家医药行业政策的影响，导致公司化学合成药 | | 及制剂的毛利率同比有所下降。感谢您的关注。 | | 8、问：对于中国医药市场规模不断扩大，公司有打算拓 | | 展其他新的药物领域吗？ | | 答：您好，随着人民生活水平的提高、老龄化进程 | | 的加快、消费者对治疗认识的提高，医疗保健需求不断 | | 增长。公司将围绕抗菌、抗病毒等相关产品及相关原料 | | 药加大研发投入。感谢您的关注！ | | 9、问：请问公司对乙酰氨基酚片目前产能情况？占公司 | | 在产品的比重目前有多少？ | | 答：您好，目前公司对乙酰氨基酚片生产经营正常， | | 产品销售额占公司工业产品销售额约为 3%左右。感谢您 | | 的关注。 | | 10、问：现阶段来看，公司主要发展战略及重心是什么？ | | 答：您好， ...

安徽丰原药业股份有限公司（以下简称"公司"）已于2023年4月20日在巨潮资 讯网（http://www.cninfo.com.cn/）上披露了《公司2022年年度报告》及其摘要。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年5月11 日（星期四）下午15:00-17:00在"丰原药业投资者关系"小程序举行2022年度网上 业绩说明会。本次说明会将采用网络远程的方式举行，投资者可登陆"丰原药业投 资者关系"小程序参与互动交流。为广泛听取投资者的意见和建议，公司提前向投 资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"丰原药业投资者关系"； 参与方式二：微信扫一扫以下二维码： 证券代码：000153 证券简称：丰原药业 公告编号：2023-027 安徽丰原药业股份有限公司 关于召开2022年度业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假记 载、误导性陈述或者重大遗漏。 投资者依据提示，授权登入"丰原药业投资者关系"小程序，即可参与交流。 出席本次业绩说明会人员：公司董事长何宏满先生、董事兼总经理汝添乐先生、 独立董 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥1,206,114,496.19, representing a 22.03% increase compared to ¥962,640,018.61 in the same period last year[3] - Net profit attributable to shareholders was ¥46,024,429.74, up 23.74% from ¥35,754,437.30 year-on-year[3] - The net profit excluding non-recurring gains and losses increased by 67.49% to ¥39,706,065.28 from ¥23,706,653.19 in the previous year[3] - Total operating revenue for Q1 2023 reached CNY 1,206,114,496.19, an increase of 21.9% compared to CNY 988,370,430.28 in Q1 2022[16] - Net profit attributable to the parent company was CNY 46,024,429.74, up 23.5% from CNY 37,194,242.35 in the same period last year[17] - Operating profit for the quarter was CNY 65,777,326.09, representing a 23.3% increase from CNY 53,357,909.46 in Q1 2022[16] - The total comprehensive income for the period was CNY 44,588,935.62, up from CNY 35,317,810.54 in the same quarter last year, an increase of 26.3%[17] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.1386, compared to CNY 0.1192 in Q1 2022, marking a 16.5% increase[17] Cash Flow - The company's cash flow from operating activities decreased by 29.16% to ¥20,045,680.47, down from ¥32,242,266.52 in the same period last year[3] - The net cash flow from operating activities for Q1 2023 was CNY 20,045,680.47, a decrease of 29.5% compared to CNY 28,298,762.02 in Q1 2022[19] - Total cash inflow from operating activities was CNY 1,034,532,225.52, while total cash outflow was CNY 1,014,486,545.05, resulting in a net cash inflow of CNY 20,045,680.47[19] - Cash flow from financing activities resulted in a net outflow of CNY 138,883,346.02, contrasting with a net inflow of CNY 5,805,131.14 in Q1 2022[19] - The ending balance of cash and cash equivalents was CNY 197,075,419.43, down from CNY 260,092,632.09 at the end of Q1 2022[19] - Total cash outflow for operating activities included CNY 84,892,708.85 in taxes paid, which increased significantly from CNY 39,729,421.07 in the previous year[19] - The company reported cash payments for purchasing goods and services amounting to CNY 679,553,466.73, an increase from CNY 653,899,669.92 in Q1 2022[19] Research and Development - R&D expenses surged by 102.31% to ¥25,035,890.83, compared to ¥12,375,233.91 in the previous year, indicating increased investment in innovation[7] - Research and development expenses increased significantly to CNY 25,035,890.83, up 102.7% from CNY 12,375,233.91 in the previous year[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,407,882,216.30, a decrease of 1.37% from ¥4,469,239,892.87 at the end of the previous year[3] - Total liabilities decreased to CNY 2,599,090,314.33 from CNY 2,714,477,751.55, a reduction of 4.2%[15] - The company's total equity increased to CNY 1,808,791,901.97, up from CNY 1,754,762,141.32, reflecting a growth of 3.1%[15] - The company's equity attributable to shareholders increased by 3.14% to ¥1,782,818,453.82 from ¥1,728,488,218.94 at the end of the previous year[3] Shareholder Information - The total number of common shareholders at the end of the reporting period is 50,171, with no preferred shareholders having restored voting rights[10] - The top 10 shareholders hold a total of 100% of the shares, with Anhui Wuwei Pharmaceutical Factory holding 10.79% (35,842,137 shares) and Anhui Bengbu Tushan Pharmaceutical Factory holding 7.68% (25,521,900 shares)[10] - The top 10 shareholders are involved in margin trading, with significant holdings through various securities accounts[11] Other Financial Metrics - The weighted average return on equity improved to 2.63%, up from 2.31% in the previous year[3] - The company recorded a 3769.82% increase in other operating expenses, amounting to ¥287,607.30, compared to ¥7,432.05 in the previous year, primarily due to increased asset write-off losses[9] - The company held a board meeting on April 7, 2023, to approve the revised plan for issuing shares to purchase assets and raise matching funds[12] - The company has implemented a restricted stock incentive plan in 2022, with certain shareholders holding restricted shares[11]

安徽丰原药业股份有限公司 2022年年度报告全文 安徽丰原药业股份有限公司 2022 年年度报告 ...

安徽丰原药业股份有限公司 2022 年第三季度报告 证券代码：000153 证券简称：丰原药业 公告编号：2022-046 安徽丰原药业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据：□是 否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入（元） | 967,901,001.56 | 10.47% | 2,865,476,079.87 | 9.39% | | 归属于上市公司股东的净利润（元） | 37,998,25 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,897,575,078.31, representing an increase of 8.84% compared to ¥1,743,408,446.49 in the same period last year[23]. - The net profit attributable to shareholders was ¥88,499,795.49, a 39.19% increase from ¥63,582,479.55 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥57,984,783.75, up 30.83% from ¥44,319,138.72 in the previous year[23]. - The net cash flow from operating activities was ¥90,733,877.39, reflecting a 19.10% increase compared to ¥76,183,345.95 in the same period last year[23]. - Basic earnings per share rose to ¥0.2835, a 39.18% increase from ¥0.2037 in the previous year[23]. - Operating profit reached 124.69 million yuan, up 41.12% compared to the same period last year[31]. - The company achieved a net increase in cash and cash equivalents of 62.20%, rising to ¥43,105,714.02 from ¥26,575,913.28[45]. - The company's operating revenue for the reporting period was ¥1,897,575,078.31, representing an increase of 8.84% compared to ¥1,743,408,446.49 in the same period last year[45]. - The operating cost increased by 15.09% to ¥1,369,704,369.76 from ¥1,190,151,163.14, resulting in a decrease in gross margin[45]. - The company reported a significant increase of 166,347.87% in fair value gains to ¥9,006,643.98 from ¥5,411.09, reflecting improved performance in financial assets[45]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,900,361,419.74, up 2.20% from ¥3,816,330,179.12 at the end of the previous year[23]. - The net assets attributable to shareholders increased to ¥1,583,664,088.94, a growth of 3.63% from ¥1,528,153,114.79 at the end of the previous year[23]. - As of the end of the reporting period, cash and cash equivalents amounted to ¥283,229,491.57, representing 7.26% of total assets, an increase from 6.44% at the end of the previous year[49]. - Accounts receivable reached ¥710,151,417.10, accounting for 18.21% of total assets, up from 16.76% year-over-year[49]. - Inventory stood at ¥568,904,757.02, slightly decreasing from the previous year's ¥569,531,788.80, maintaining a stable proportion of 14.59% of total assets[49]. - Total liabilities increased to CNY 2,287,068,396.72 from CNY 2,258,628,241.31, showing a growth of about 1.3%[130]. - The total equity attributable to shareholders increased to CNY 1,583,664,088.94 from CNY 1,528,153,114.79, reflecting a growth of approximately 3.6%[130]. Research and Development - Research and development expenses decreased by 45.86% to ¥20,202,265.27 from ¥37,314,532.78, indicating a reduction in R&D investment[45]. - The company focuses on new drug research and development, holding multiple national first and second-class new drug varieties and several proprietary intellectual property products[31]. - The company has made progress in the development of key generic drug products, with several products approved for production and clinical trials[42]. Corporate Governance and Compliance - The company has established a complete corporate governance structure and internal control system to ensure fairness for all shareholders[82]. - The company emphasizes compliance with laws and regulations, integrating social responsibility into its corporate strategy and operations[81]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[87]. - The company has not engaged in any violations regarding external guarantees during the reporting period[88]. - The semi-annual financial report has not been audited[89]. Environmental Responsibility - Likang Pharmaceutical has established an online monitoring system for COD, ammonia nitrogen, and pH to ensure pollutant discharge meets standards[76]. - Tushan Pharmaceutical operates a wastewater treatment facility with a capacity of 300 tons per day, connected to environmental monitoring systems[76]. - The company emphasizes safety production, environmental protection, and energy conservation, implementing strict safety management and emergency response plans[81]. - The company actively promotes green development by implementing energy-saving projects, including water storage cooling and environmental boiler renovations[82]. Market and Business Strategy - The main business includes pharmaceutical manufacturing and commercial circulation, with a comprehensive pharmaceutical supply service system established[31]. - The sales model includes both new drugs and generic drugs, utilizing a "招商+自营" approach for comprehensive market coverage[39]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[130]. Risks and Challenges - The company is facing risks from policy changes in the pharmaceutical industry, including drug procurement and price negotiations, which may impact future performance[65]. - The company emphasizes the high risks associated with new drug development, which involves significant investment and long cycles[6]. - The company has invested in venture capital funds, which may have long investment recovery periods and face risks from macroeconomic factors[65]. Shareholder Information - The total number of shares after the recent changes is 312,141,230, with 99.95% being unrestricted shares[112]. - The largest shareholder, Anhui Province Wuwei Pharmaceutical Factory, holds 35,842,137 shares, representing 11.48% of the total shares[114]. - The total number of shareholders at the end of the reporting period is 34,852[113]. - The company has not undergone any changes in its controlling shareholder during the reporting period[118]. Financial Instruments and Accounting Policies - The company adheres to the Chinese Accounting Standards, ensuring that its financial statements accurately reflect its financial position and results as of June 30, 2022[164]. - Financial instruments are recognized when the company becomes a party to the contract, with specific criteria for derecognition of financial assets and liabilities[179]. - The company uses the expected credit loss model to assess impairment for loan commitments and financial guarantee contracts[182]. - The company recognizes cash equivalents as short-term, highly liquid investments that are easily convertible to known amounts of cash[176].

Financial Performance - The company's operating revenue for 2021 was ¥3,501,668,742.45, representing a 5.43% increase compared to ¥3,321,182,365.33 in 2020[24] - The net profit attributable to shareholders for 2021 was ¥114,597,454.55, up 10.49% from ¥103,720,155.65 in the previous year[24] - The net profit after deducting non-recurring gains and losses was ¥69,940,271.86, reflecting a 21.38% increase from ¥57,622,979.48 in 2020[24] - The basic earnings per share for 2021 was ¥0.3671, an increase of 10.47% compared to ¥0.3323 in 2020[24] - The total assets at the end of 2021 were ¥3,816,330,179.12, a 4.95% increase from ¥3,636,207,572.40 at the end of 2020[24] - The net assets attributable to shareholders increased by 8.11% to ¥1,528,153,114.79 at the end of 2021 from ¥1,413,489,476.40 in 2020[24] - The net cash flow from operating activities for 2021 was ¥237,881,716.28, down 18.74% from ¥292,753,328.44 in 2020[24] - The weighted average return on equity for 2021 was 7.79%, slightly up from 7.57% in 2020[24] Quarterly Performance - The company's total revenue for Q1, Q2, Q3, and Q4 of 2021 was approximately ¥863.88 million, ¥879.53 million, ¥876.17 million, and ¥882.09 million respectively, showing a steady increase throughout the year[28] - The net profit attributable to shareholders for the same quarters was ¥27.29 million, ¥36.30 million, ¥26.63 million, and ¥24.38 million, indicating fluctuations in profitability[28] - The net profit after deducting non-recurring gains and losses was ¥23.57 million in Q1, ¥20.75 million in Q2, ¥17.62 million in Q3, and dropped to ¥8.00 million in Q4, reflecting a significant decline in the last quarter[28] - The net cash flow from operating activities showed a strong increase, with Q4 reaching ¥117.58 million, compared to ¥36.64 million in Q1, indicating improved cash generation capabilities[28] Government Support and Industry Trends - The company received government subsidies amounting to ¥38.00 million in 2021, which were closely related to its normal business operations[29] - The pharmaceutical industry is undergoing significant reforms, including the promotion of centralized procurement and consistency evaluation of generic drugs, which are expected to enhance the industry's quality and efficiency[32] - The government has implemented policies to support the development of traditional Chinese medicine, which may positively impact the company's operations in this sector[35] Research and Development - The company is focused on new drug research and development, holding multiple national first and second-class new drug varieties and several proprietary intellectual property products[37] - The company has a research and development platform supported by a national-level enterprise technology center[44] - The company’s R&D investment increased, focusing on innovative drug development and the consistency evaluation of key generic drugs[48] - Research and development expenses amounted to approximately CNY 70.06 million, a decrease of 7.17% from CNY 75.47 million in 2020[65] - The number of R&D personnel increased to 166 in 2021, a rise of 3.75% from 160 in 2020[67] - The proportion of R&D investment to operating revenue decreased to 2.69% in 2021 from 2.79% in 2020, a decline of 0.10%[67] Product and Market Strategy - The company plans to launch new products, including injectable parecoxib sodium and propofol emulsion injection, which are expected to enhance profit growth[66] - The company operates under a unified procurement system for bulk materials to ensure stable and reliable quality[42] - The company employs a sales model that combines "招商+自营" to achieve full coverage of hospitals, retail, and third-party terminals[42] - The company is focusing on optimizing its business structure and enhancing profitability by targeting major and core customers[48] Financial Management and Governance - The company has established a sound corporate governance structure in accordance with relevant laws and regulations, ensuring accurate and complete information disclosure[91] - The company operates independently from its controlling shareholders, maintaining separate assets, personnel, and financial systems[93] - The company reported a stable management team with no changes in directors, supervisors, or senior management during the reporting period[98] - The company is committed to maintaining high standards of corporate governance and compliance, as reflected in its board composition[102] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 5.8414 million[107] Environmental Responsibility - The company emphasizes the integration of social responsibility into its corporate strategy and operations, focusing on economic benefits and social contributions[139] - The company is actively pursuing energy-saving and emission-reduction projects, including water storage cooling projects and environmental boiler renovations[139] - Likan Pharmaceutical has completed the construction of pollution control facilities, ensuring compliance with emission standards[134] - Tushan Pharmaceutical operates a wastewater treatment facility with a capacity of 300 tons per day, connected to environmental monitoring systems to ensure compliance[134] Risks and Challenges - The company faces risks from policy changes in the pharmaceutical industry, including drug consistency evaluation and centralized procurement[87] - The company is at risk of increased production costs due to rising raw material prices, and will implement centralized procurement and price negotiations to mitigate these costs[88] - Environmental risks are present as raw material production generates waste, leading to increased operational costs; the company will enhance environmental investments to ensure compliance with regulations[88] Shareholder Information - The company has a total of 312,141,230 shares, with 99.95% being unrestricted shares[180] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 11.48% of the shares, totaling 35,842,137 shares[183] - The company has a total of 28,779 shareholders at the end of the reporting period[183] - The top ten unrestricted shareholders hold a total of 108,026,115 shares, with the largest shareholder, Anhui Wuwei Pharmaceutical Factory, owning 35,842,137 shares, representing 11.56% of the total share capital[184]

Financial Performance - The company's revenue for Q1 2022 was ¥962,640,018.61, representing an increase of 11.43% compared to ¥863,882,165.30 in the same period last year[4] - Net profit attributable to shareholders was ¥35,754,437.30, up 31.04% from ¥27,285,357.83 year-on-year[4] - Basic earnings per share increased to ¥0.1145, reflecting a growth of 31.01% compared to ¥0.0874 in the previous year[4] - Net profit for Q1 2022 was ¥36,256,746.22, representing a 36.5% increase from ¥26,599,550.42 in Q1 2021[16] - Earnings per share (EPS) for Q1 2022 was ¥0.1145, compared to ¥0.0874 in the previous year, indicating a growth of 30.9%[17] - The company reported a total comprehensive income of ¥33,878,005.49 for Q1 2022, compared to ¥27,488,070.73 in the previous year, an increase of 23.5%[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,024,285,151.83, a rise of 5.45% from ¥3,816,330,179.12 at the end of the previous year[4] - Total current assets increased to ¥1,868,813,241.75 from ¥1,694,770,901.78, reflecting a growth of approximately 10.25%[11] - Accounts receivable rose to ¥756,116,505.67 from ¥653,484,276.79, an increase of about 15.77%[11] - Inventory increased to ¥613,609,611.00 from ¥569,531,788.80, showing a growth of approximately 7.73%[12] - Total current liabilities increased to ¥2,124,879,483.68 from ¥1,920,416,837.38, reflecting a growth of approximately 10.65%[12] - The company's total liabilities increased to ¥2,432,705,208.53 from ¥2,258,628,241.31, reflecting a rise of 7.7%[16] - Total equity attributable to shareholders of the parent company rose to ¥1,561,450,729.61, up from ¥1,528,153,114.79, an increase of 2.2%[16] Cash Flow - The net cash flow from operating activities decreased by 12.00% to ¥32,242,266.52 from ¥36,640,215.97 in the same period last year[4] - Cash inflow from operating activities totaled ¥986,358,729.17, compared to ¥929,172,366.57 in the same quarter last year, marking a 6.1% increase[18] - The net cash flow from financing activities rose by 116.76% to ¥5,924,756.15, primarily due to reduced cash payments for interest[7] - Cash inflow from financing activities was CNY 251,716,916.67, down 13.4% from CNY 290,484,611.11 in the previous year[19] - The ending balance of cash and cash equivalents was CNY 238,890,232.29, down from CNY 264,393,855.48, a decrease of 9.7% year-over-year[19] - The company paid CNY 231,100,000.00 in debt repayments, which is a decrease from CNY 269,000,000.00, reflecting a reduction of 14.1%[19] Research and Development - The company's research and development expenses decreased by 51.56% to ¥11,956,114.40 from ¥24,684,328.32 year-on-year[7] - Research and development expenses decreased to ¥11,956,114.40 from ¥24,684,328.32, a reduction of 51.5% year-over-year[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,665[9] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 11.48% of shares, totaling 35,842,137 shares[9] - The top ten shareholders include several state-owned enterprises, indicating a concentration of ownership[9] Government Subsidies - Government subsidies recognized in the current period amounted to ¥12,170,989.18, a significant increase of 150.99% compared to ¥4,849,180.58 in the previous year[7] Operational Insights - The company is exploring market expansion strategies and new product development initiatives[10] - Total operating costs amounted to ¥922,389,675.57, up from ¥822,318,183.44, reflecting a year-over-year increase of 12.8%[15] - Cash received from sales of goods and services was ¥930,486,210.97, an increase from ¥871,382,239.48, reflecting a growth of 6.8% year-over-year[18] Audit Information - The company did not conduct an audit for the first quarter report[20]

Financial Performance - The company's revenue for Q3 2021 was ¥876,165,996.14, representing a 3.26% increase compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥26,630,100.86, a significant increase of 106.52% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,620,720.44, up 256.70% from the previous year[3] - Basic earnings per share for Q3 2021 was ¥0.0853, an increase of 106.54% year-on-year[3] - The total operating revenue for the third quarter of 2021 was CNY 2,619,574,442.63, an increase of 7.98% compared to CNY 2,426,272,151.86 in the same period last year[17] - The net profit for the third quarter was CNY 88,341,496.74, representing a 25.3% increase from CNY 70,492,698.84 in the previous year[19] - The earnings per share (EPS) for the period was CNY 0.2890, compared to CNY 0.2263 in the same quarter last year, indicating a growth of 27.8%[19] - The total comprehensive income for the quarter was CNY 88,520,393.89, compared to CNY 59,471,810.67 in the same period last year, indicating a significant increase[19] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥3,767,473,524.33, a 3.61% increase from the end of the previous year[3] - Total current assets as of September 30, 2021, amount to ¥1,705,883,434.34, a decrease from ¥1,738,288,251.02 at the end of 2020[15] - Total assets as of September 30, 2021, are ¥3,767,473,524.33, up from ¥3,636,207,572.40 at the end of 2020[15] - The total liabilities as of the end of the third quarter were CNY 2,232,586,373.98, slightly up from CNY 2,188,230,845.23[17] - Total liabilities amounted to ¥1,800,000,000.00, indicating a stable financial position despite fluctuations in cash flow[26] - Total liabilities amounted to CNY 2,188,230,845.23, with current liabilities at CNY 2,065,177,727.62[27] - Non-current liabilities totaled CNY 123,053,117.61, including long-term borrowings of CNY 27,037,500.00[27] Shareholder Information - Shareholders' equity attributable to the parent company was ¥1,503,707,010.25, up 6.38% from the previous year[3] - Total number of common shareholders at the end of the reporting period is 29,549[11] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 11.48% of shares, totaling 35,842,137 shares[12] - The total equity attributable to shareholders of the parent company increased to CNY 1,503,707,010.25 from CNY 1,413,489,476.40, marking a growth of 6.4%[17] - Total equity reached CNY 1,447,976,727.17, with attributable equity to shareholders at CNY 1,413,489,476.40[27] Cash Flow - The operating cash flow net amount for the year-to-date was ¥120,300,008.93, reflecting a 167.02% increase compared to the same period last year[3] - The company reported a total cash flow from operating activities of CNY 123,389,224.71 for the quarter, up from CNY 98,300,540.59 year-over-year[19] - Total cash inflow from operating activities reached ¥3,109,896,047.15, compared to ¥2,829,637,923.69 in the prior period, indicating a growth of approximately 9.9%[22] - Cash outflow for purchasing goods and services was ¥2,122,986,880.24, an increase from ¥1,809,836,655.29, reflecting a rise of about 17.3%[22] - The net cash flow from investing activities was -¥109,571,881.37, slightly improved from -¥111,972,916.56 in the previous period[23] - Cash inflow from financing activities totaled ¥763,766,257.12, down from ¥908,405,007.38, showing a decrease of approximately 15.9%[23] - Cash outflow for debt repayment was ¥729,500,000.00, compared to ¥843,677,121.00 previously, indicating a reduction of about 13.5%[23] - The ending balance of cash and cash equivalents was ¥240,432,924.87, an increase from ¥220,688,650.37, marking a growth of approximately 8.5%[23] Research and Development - The company reported a significant increase in R&D expenses, totaling ¥73,446,859.39, which is a 40.49% increase year-on-year[8] - Research and development expenses for the quarter were CNY 50,606,084.29, compared to CNY 48,898,789.79 in the previous year, reflecting an increase of 2.4%[19] - The company has ongoing development expenditures of ¥73,446,859.39, up from ¥52,278,192.01[15] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Other Financial Information - The company received government subsidies amounting to ¥12,176,376.66 during the reporting period, contributing to its non-recurring gains[5] - The company experienced a 222.19% increase in long-term borrowings, reaching ¥87,111,283.33, indicating a strategic shift in financing[9] - The company implemented new leasing standards affecting the financial statements, which may impact future reporting and financial metrics[24] - The report for the third quarter of 2021 was not audited[28] - The company has implemented new leasing standards starting from 2021, with no retrospective adjustments made to prior comparative data[28] - The total amount of other payables was CNY 542,281,489.43[27] - The company has a deferred income of CNY 77,262,652.87[27] - The total amount of undistributed profits was CNY 518,891,038.45[27] - The company’s total current liabilities include a significant portion of short-term debts[27]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,743,408,446.49, representing a 10.50% increase compared to CNY 1,577,762,403.83 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was CNY 63,582,479.55, up 10.10% from CNY 57,751,474.43 year-on-year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 44,319,138.72, reflecting a 15.34% increase from CNY 38,423,723.93 in the previous year[26]. - The total profit before tax was CNY 90,139,500, reflecting a 16.99% increase year-on-year[33]. - The operating profit was CNY 88,356,300, marking a 15.89% increase from the previous year[33]. - The company reported a total profit of CNY 90,139,512.10 for the first half of 2021, compared to CNY 77,047,786.78 in the same period last year, marking a 17.0% increase[123]. Cash Flow and Assets - The net cash flow from operating activities was CNY 76,183,345.95, a significant increase of 200.10% compared to CNY 25,385,836.31 in the same period last year[26]. - The company's cash and cash equivalents increased by 152.54%, reaching CNY 26,575,913.28[38]. - Cash and cash equivalents at the end of the period increased to ¥279,350,705.24 from ¥204,739,118.44, marking a growth of 36.3%[130]. - The total assets at the end of the reporting period were CNY 3,799,524,741.03, which is a 4.49% increase from CNY 3,636,207,572.40 at the end of the previous year[26]. - The total current assets amounted to ¥1,792,176,172.35, compared to ¥1,738,288,251.02 at the end of 2020, reflecting an increase of approximately 3.1%[114]. Shareholder Information - The total number of shares is 312,141,230, with 99.95% being unrestricted shares[99]. - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 11.48% of shares, totaling 35,842,137 shares[102]. - The company did not distribute cash dividends or issue bonus shares[9]. - The company did not experience any major litigation or arbitration matters during the reporting period[80]. Research and Development - The company reported a significant increase in R&D expenses, totaling CNY 37,314,532.78, which is an 83.66% increase compared to the previous year[38]. - The company operates in the pharmaceutical manufacturing industry, focusing on the production and sales of various drug forms including large-volume injections and small-volume injections[147]. Subsidiaries and Investments - The company established a new wholly-owned subsidiary, Anhui Fengyuan Weikang Raw Material Pharmaceutical Co., Ltd., through its subsidiary, which may impact overall production and performance positively[58]. - The consolidated financial statements include 17 subsidiaries, all of which are wholly owned or controlled by the company[149]. Financial Position and Equity - The total equity at the end of the reporting period is CNY 895,613,733.62, down from CNY 924,105,564.22 at the beginning of the year, reflecting a decrease of approximately 3.08%[140]. - The total liabilities increased to CNY 2,290,815,494.18 from CNY 2,188,230,845.23, reflecting a growth of about 4.7%[116]. - The company's retained earnings rose to CNY 582,473,518.00 from CNY 518,891,038.45, an increase of approximately 12.2%[116]. Compliance and Governance - Environmental compliance measures are in place, with all pollution control facilities operational and meeting national standards[70]. - The company confirmed that there were no major related party transactions during the reporting period[87]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months[152]. Financial Reporting and Standards - The financial statements are prepared in accordance with the Chinese Accounting Standards and reflect the company's financial position as of June 30, 2021[154]. - The semi-annual financial report was not audited[78]. Risk Management - The company faced risks from the implementation of drug policies such as consistency evaluation and centralized procurement, which could alter market competition dynamics[60]. - The company is actively monitoring investment risks associated with venture capital funds due to potential long investment recovery periods and market fluctuations[60].